A Study for HSK47388 in Participants With Ulcerative Colitis
Condition(s) studied
Investigational drug(s) / intervention(s)
HSK47388: Participants will be randomized to receive HSK47388, orally starting at Week 0 . At Week-12, all participants will be evaluated for clinical response and responders will enter the maintenance study.
Placebo: Participants will be randomized to receive Placebo, orally starting at Week 0 . At Week-12, all participants will be evaluated for clinical response and responders will enter the maintenance study.
Study summary
The purpose of this protocol is to evaluate the efficacy and safety of HSK47388 as therapy in participants with moderately to severely active ulcerative colitis .
Eligibility
Primary outcome measure(s)
- The proportion of patients with clinical response — Week 12
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sir Run Run Shaw Hospital | Hangzhou | China | Recruiting |
More Haisco Pharmaceutical Group Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07335055 on ClinicalTrials.gov ↗ ← All trials in China